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Abstract 
 
18F-FAC (1-(2’-deoxy-2’-[18F]fluoro-β-D-arabinofuranosyl)-cytosine) is an important 2’-
fluoro-nucleoside-based PET tracer that has been used for in vivo prediction of response to 
the widely used cancer chemotherapy drug gemcitabine. Previously reported synthetic routes 
to 18F-FAC have relied on early introduction of the 18F radiolabel prior to attachment to 
protected cytosine base. Considering the 18F radiochemical half-life (110 minutes) and the 
technical challenges of multi-step syntheses on PET radiochemistry modular systems, late-
stage radiofluorination is preferred for reproducible and reliable radiosynthesis with in vivo 
applications. Herein, we report the first late-stage radiosynthesis of 18F-FAC. Cytidine 
derivatives with leaving groups at the 2’-position are particularly prone to undergo anhydro 
side product formation upon heating due to their electron density at the 2-carbonyl 
pyrimidone oxygen. Our rationally developed fluorination precursor showed an improved 
reactivity-to-stability ratio at elevated temperatures. 18F-FAC was obtained in radiochemical 
yields (RCY) of 4.3-5.5% (n = 8, decay-corrected from end of bombardment (EoB)), with 
purities ≥98% and specific activities ≥63 GBq/µmol. The synthesis time was 168 min. 
Keywords: nucleosides • Positron Emission Tomography • radiochemistry • radiopharmaceuticals • 
computational chemistry 
Introduction 
Nucleoside derivatives represent an important emerging class of biomarkers for Positron 
Emission Tomography (PET) imaging.[1] For example, the clinically approved proliferation 
biomarker 18F-FLT (3’-deoxy-3’-[18F]fluoro-L-thymidine) is accessible via an effective 
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radiochemical synthesis in high radiochemical yield (RCY) and purity suitable for human 
production under GMP guidelines.[2] Hence, 18F-FLT is now commonly used for the early 
detection of various cancers and the evaluation of treatment response.[3] Especially in high-
grade tumours it appears to be more powerful in predicting treatment response and survival 
than 18F-FDG, as measured by standard uptake values of 18F-FLT directly corresponding to 
cell proliferation shown by the Ki-67 proliferation index.[4]  
Cytidine-based radiotracers for PET imaging such as 18F-FAC (1, Figure 1) and 1-(2´-
deoxy-2´-[18F]fluoroarabinofuranosyl)-5-methylcytosine (18F-FMAC, 2, Figure 1) have been 
previously shown to be successful as predictors of response for nucleoside analogue based 
treatment of cancer[5,6] as well as local immune activation in mouse models.[7] As such, 18F-
FAC has been used for response prediction to the widely used chemotherapy drug 
gemcitabine.[5] Gemcitabine is frequently used for (combination) chemotherapy of a number 
of solid tumors such as pancreatic, non-small lung, breast and bladder cancer. Importantly, 
gemcitabine efficacy is compromised by poor cellular uptake by nucleoside transporters, 
variable activity of the essential deoxycytidine kinase (dCK) activating enzyme, and rapid 
deactivating metabolism by cytidine deaminase (CDA). In addition, serious dose-limiting 
toxicities are associated with this chemotherapy drug.[8] Prediction of patient response to 
gemcitabine chemotherapy would therefore be an important milestone towards personalised 
patient chemotherapy in the cancer clinic. 
Given the close structural resemblance to gemcitabine, 18F-FAC was found to have a 
comparably high affinity for deoxycytidine kinase (dCK), a rate-limiting enzyme in the 
nucleoside salvage pathway. Hence, in vivo imaging determined dCK-positive and –negative 
tumours. Furthermore, an additional study showed that 18F-FMAC PET imaging provides 
information about cytidine deaminase (CDA) enzymatic activity in vivo which is related to 
gemcitabine resistance.[6] Together, cytidine-based PET probes enable further conclusions 
towards personalised chemotherapy which, considering the low (≤ 20%) response rates and 
severe side effects, could lead to significantly improved treatment efficacy.[8] 
2’-[18F]arabinocytidines such as 18F-FAC and 18F-FIAC (3, Figure 1) have been 
synthesized in high purities using an early stage 18F introduction strategy.[9] However, this 
synthetic approach limits reliable and reproducible production on commercially available 
synthesis modules for human application.[10] For instance, multiple steps after 18F 
introduction with an additional purification step due to the formation of the D- and L-
isomers, as well as the use of toxic substances such as hydrogen bromide, make the 
translation to automated synthesizers difficult. These challenges go hand in hand with 
reproducibility issues when it comes to Quality Control (QC) in clinical practice according to 
the British/European/American Pharmacopeia (BPh/Ph. Eur./USP). Furthermore, as the 
number and space in hot cells is limited multiple-step radiosyntheses should preferably be 
replaced by shorter and less complex synthetic procedures. Lazari et. al. recently presented a 
newly designed radiosynthesis module system which furnished the nucleoside analogues 18F-
FMAU and 18F-FAC in good overall radiochemical yields (46% and 31% respectively, 
decay-corrected) and with acceptable reproducibility following early stage fluoride 
introduction.[11] Overall synthesis times were reported to be 165-170 minutes in each case. 
The flexible radio-synthesizers developed are described as being suitable for both the 
development and production of different radiotracers for applications in PET. 
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Figure 1. Chemical structures of the cytidine-based biomarkers 18F-FAC, 18F-FMAC and 18F-FIAC (1-3), and 
the anticancer drug gemcitabine. 
 
The aim of this study was to develop a novel and straightforward synthetic approach 
towards 18F-FAC that could be applied to the radiosynthesis of related cytidine-based 
radiotracers. A more straightforward radiosynthesis similar to the 18F-FDG synthesis in 
combination with innovative radio-synthesizers would enable a faster transition from tracer 
development to clinical application. Late-stage 18F-introduction at the 2’-arabino position of 
an intact nucleoside towards nucleoside-based radiotracers was previously considered as 
difficult.[12] However, Alauddin and co-workers recently developed a novel radiosynthesis of 
the uridine analogue 18F-FMAU based on a late-stage 18F-introduction approach in order to 
increase possibilities for making nucleoside based PET tracer suitable for clinical 
applications.[10,12] The key towards a stable precursor that would be less likely to undergo 
anhydro side product formation (e.g. Scheme 1) due to neighbouring group participation was 
the introduction of a good electron withdrawing N-protecting group(s). Since the amino-
group at the 4-position of cytidine derivatives likely enhances the nucleophilicity of the 2-
carbonyl oxygen, potential precursor molecules containing a leaving group at the 2’-position 
are even more prone to undergo anhydro formation especially at high temperatures (≥ 75 °C). 
Thus, a reasonable radiofluorination precursor must combine sufficient reactivity with 
stability towards heat as well as basic conditions. In this study we present for the first time a 
late-stage radiofluorination approach towards the 18F-labelled cytidine derivative 18F-FAC. 
Experimental Section 
Radiosynthetic procedures 
N4-bis-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-deoxy-2’-[18F]fluoroarabinocytidine (25). 
[18F]fluoride was trapped on a QMA cartridge (equilibrated with 5% NaHCO3-solution (5 
mL) and water (5 mL)) before it was eluted with an aqueous solution (0.7 mL) of KHCO3 
(22.6 mg/mL) and kryptofix K222 (22.6 mg/mL) in MeCN. The resulting 18F/KHCO3/K222-
complex was dried by co-evaporation under reduced pressure and a stream of nitrogen. The 
drying process was repeated 3 times (3 × 1 mL MeCN). A solution of precursor (23) (10 mg, 
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14.5 μmol) in DMF (0.3 mL) was then added and the resulting mixture was stirred at 110 °C 
for 20 min. The crude mixture was either analyzed directly for determination of 18F-
incorporation (radio-TLC) or passed through an Alumina-Sep-Pak cartridge (equilibrated 
with water (5 mL)) for characterization (radio-HPLC). The 18F-labelled intermediate was 
eluted with EtOAc (2 mL) and an aliquot (0.2 mL) of the mixture was analyzed by analytical 
HPLC using co-elution with the non-radioactive reference compound (24). Rt = 17.2 min, 
MeCN/H2O 9:1, 1 mL min-1, ≥87%. Radio-TLC. Rf = 0.6 (4% MeOH/DCM). 
 
18F-FAC (1). After elution of the 18F-labelled intermediate (25) with EtOAc into a new 
reaction V-vial the solvent was removed under reduced pressure and a stream of nitrogen at 
80 °C. 2N HCl-solution (0.3 mL) was added to the dried residue followed by stirring at 90 °C 
for 15 min. The solution was then neutralized with 2N NaOH solution (0.3 mL). The 
resulting mixture was loaded onto a semi-preparative HPLC column via a 10 mL injection 
loop. The fraction containing 18F-FAC was collected after 22.5 min with 3% MeCN in H2O 
and a flow rate of 3.5 mL min-1. The appropriate fraction was flushed through a sterile filter 
and concentrated via evaporation on the module (100 °C under a stream of nitrogen for 10 
min.). The residue was taken up in sterile saline. An aliquot (0.2 mL) of the mixture was 
analyzed by analytical HPLC using co-elution with the non-radioactive reference compound 
27, Rt = 13.8 min, 3% MeCN/H2O, 1 mL min-1, ≥98 %. A carrier-added synthesis was 
performed according to the above procedure and the product 19F/18F-FAC was saved for 
decay for 20 half-lives (≈ 2 days) and subsequently analyzed by mass spectrometry; MS (70 
eV): m/z (%): 245.4 (5) [(M+H)+], 267.7 (95) [(M+Na)+]. 
 
Computational Methods 
MOE 2010.10 software was used to design each compound and to explore possible 
conformations. The searching method applied was LowModMD that generates conformations 
using a short run of Molecular Dynamics (MD) at constant temperature followed by an all-
atom energy minimization. Among the conformations, sixteen of them were selected for each 
compound for quantum mechanics (QM) evaluation. QM calculations were executed for the 
selected conformations with the GAMESS[13] software. A geometry optimisation was 
performed in vacuo, using analytical energy gradients with the Restricted Hartree Fock 
(RHF) wave function. The 3-21G split valence basis set was used and diffuse sp shell was 
added to heavy atoms. The initial hessian was guessed and the convergence gradient 
tolerance was set to 0.0005 Hartree/Bohr. The electrostatic potential was calculated at points 
determined by Michael Connolly algorithm on the surface of van der Waals fused spheres. 
Atomic charges were consequently fitted to this potential. The partial net charges of atoms of 
interest were gathered from each molecule conformation and values were averaged. 
Results and Discussion 
Precursor design 
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In order to develop a new precursor for radiofluorination of the 2’-arabino position of 
cytidine derivatives the idea of radiofluorination of an intact nucleoside moiety was applied. 
The main challenge of this new approach is the rational design of precursors that combine 
reactivity and stability in a way that the 18F-nucleophile can be incorporated at high 
temperatures resulting in acceptable conversion rates while heat-mediated anhydro-formation 
is kept to a minimum. A quantitative method for the characterization of precursor stabilities 
was desirable prior to synthesis. The electric charge density of the 2-carbonyl oxygen of the 
pyrimidone moiety was determined using theoretical methods for the potential to undergo an 
intramolecular nucleophilic attack at the 2’-position. Hence, the net electric charge of the 2-
carbonyl oxygen of a family containing N4-substituted cytidine derivatives (4-8, Figure 2) 
was calculated using quantum chemical calculations with Restricted Hartree Fock (RHF) 
wave function and the 3-21G basis set. 
       Additionally, selected uridine derivatives (9-11, Figure 2) were included in this study in 
order to obtain both a reference value as well as a measurement of how the substitution of the 
4-carbonyl group (uridines) by an amino group (cytidines) impacts the electric charge density 
at the 2-carbonyl oxygen. The N-substituents were chosen with regard to both their synthetic 
accessibility and deprotection mechanisms that would be suitable for radiochemical syntheses 
in terms of subsequent efficient removal. The N3-nitro-2’-(methanesulfonyl)uridine (11) was 
considered as a standard value as a N3-nitro-2’-(trifluoromethanesulfonyl)uridine derivative 
was previously reported as successfully synthesized and thermal stable.[14] However, the 
radiofluorination method could not be applied to a N3-nitro-uridine-based precursor. 
 
Figure 2. Selected cytidine and uridine based nucleosides for electric charge density calculations at the 2-
carbonyl oxygen. 
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The results shown below (Table 1) indicate that the electron density at the 2-carbonyl 
oxygen is reduced when H-substitution at the N4 (N3 for uridine derivatives) with an electron-
withdrawing group is performed. Furthermore, it shows that the stronger the electron-
withdrawing effect of the substituent(s) the lower the calculated electron density Ω at the 2-
carbonyl oxygen. For instance, double N4-Boc-protection (7) decreases the electron density 
more than single N4-Boc-protection (6) and N4-monoacetylation (5), respectively. 
 
Table 1. Calculated electron density Ω of selected cytidine (4-8) and uridine derivatives (9-11). 
 
Compounds 5 and 7 were synthesized (see synthesis section and Supporting 
Information) and subsequently tested for their affinity to undergo heat-mediated 
decomposition by forming the appropriate anhydro-compounds 12 and 13. First, a NMR 
sample of compound 5 in d6-DMSO was heated up to 50 °C. 1H-NMR spectra were recorded 
hourly. Figure 3 shows that almost full conversion to anhydro compound 12 occurred after 2h 
(Scheme 1).  
Chemical shifts of the amino proton (11.5 to 12.25 ppm) and the ribose protons 
clearly show the conversion into the cyclic nucleoside compound (Figure 3). Furthermore, the 
vanishing signal of the mesyl group at 3.5 ppm also indicates decomposition as the free 
mesylate is expected to have a different chemical shift that indeed could be observed at 
around 2.3 ppm next to the methyl-signal of the acetamide. 13C-NMR data after 1h incubation 
showed 24 instead of 12 signals of pure compound 5. Additionally, ESI-MS was performed 
in order to show the change in the molecular mass. The m/z-signal 268 [M + H]+ further 
confirmed generation of anhydro compound 12. 
 
Scheme 1. Heat-mediated intramolecular cyclization towards 12 in d6-DMSO. 
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Figure 3. Heat-mediated anhydro formation of 12. After only 2 hours at 50 °C nearly full conversion could be 
observed by 1H NMR analysis. 
 
The double N4-Boc-protected compound (7), however, showed significantly increased 
thermal stability as shown in Scheme 2 and Figure 4. Even though a tiny set of additional 
peaks appeared after 2 hours at 80 °C the observed stability of compound 7 looked promising 
with regard to 18F-radiolabeling reactions. 
 
 
Scheme 2. Increased thermal stability of 7. No significant formation of side product (13) could be observed (in 
d4-MeOD). 
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Figure 4. Recorded 1H-NMR spectra of the purified compound (7) after 0, 60 and 120 min at 80 °C. The 
absence of additional peaks indicate no or minimal anhydro formation through increased thermal stability. 
 
Hence, the calculated and experimental data lead to 3 major conclusions: 1. The 
electron density at the 2-carbonyl oxygen of the pyrimidine moiety can be used as a 
measurement for its ability to undergo intramolecular cyclization resulting in the appropriate 
2,2’-anhydro compounds. 2. Electron withdrawing groups have a measurable/quantifiable 
effect on the electron density at the 2-carbonyl oxygen. 3. Depending on the strength of its 
electron withdrawing nature a N4(N3)-protecting group influences the thermal stability of the 
nucleoside analogue. Finally, an N,N-diBoc fluorination precursor was selected for 
radiofluorination studies. 
 
Synthesis 
 
The synthesis of test compound 5 was carried out with the selective 3’- and 5’-
protection of N-acetylcytidine (14) using TIPDSCl2 in pyridine yielding compound 15 in 
good yield which was consecutively mesylated at the 2’-position using an excess of MsCl and 
TEA in DCM furnishing compound 16. Subsequent removal of the silica-based protecting 
group using TBAF in anhydrous THF at low temperatures gave test compound 5 which was 
purified immediately and characterized due to its high ability to undergo anhydro formation 
(Scheme 3). 
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Scheme 3. Reagents and conditions: a) TIPDSCl2, pyridine, 0 °C – r.t., 12 h, 87 %; b) MsCl, TEA , DCM, 0 °C 
– r.t., 2 h, 81 %; c) TBAF, THF, -10 °C, 30 min, 53 %. 
The synthesis of precursor (23) started with commercially available cytidine (17) which 
was first converted into the 3’- and 5’- protected nucleoside 18 using TIPDSCl2 and pyridine 
at room temperature as previously described.[8] Subsequent TMS-protection furnished 19 
which was followed by double N4-Boc protection using excess of Boc2O (5-6 eq.) and 
DMAP which gave compound 20 in good yield. Selective removal of the TMS-group using 
p-TsOH was performed at -5 °C to give intermediate 21. Subsequent mesylation of the free 
2’-hydroxy group was performed in high yield to form compound 22. TBAF-mediated 
removal of the bidendate protecting group had to be carried out at lower temperatures (~ -10 
°C) in order to avoid significant decrease in yield probably due to single Boc-group removal. 
Purified compound 7 was then converted into fluorination precursor 23 using 3,4-dihydro-
6H-pyran in excess. Highly purified precursor 23 was obtained in 9% overall yield from 17 
(Scheme 4). 
The choice of the leaving group as well as the protecting group is based on a previous 
study[10] that found that 3’/5’-THP-protection of uridine derivatives gave the best 
radiochemical yields and a 2’-mesyl group an appropriate balance between stability and 
leaving group abilities. Furthermore, our pilot studies showed that the appropriate tosyl- and 
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nosyl-containing counterparts already decomposed during purification. Furthermore, even 
though double THP-protection makes NMR analysis complex (mixture of diastereomers) the 
later removal of these groups was straightforward. 
 
Scheme 4. Reaction conditions: a) TIPDSCl2, pyridine, 0 °C – r.t., 18 h, 81 %; b) TMSCl, TEA , DCM, 0 °C – 
r.t., 2 h, 83 %; c) Boc2O, DMAP, DCM, r.t, 5 h, 77 %; d) p-TsOH, THF, -5 °C, 66-78 %; e) MsCl, TEA, DCM, 
0 °C, 90 %; f) TBAF, THF, -10 °C, 70-80 %, g) DHP, pTsOH, DCM, 0 °C - RT, 6-8 h, 45-56 %. 
Firstly, cold fluorination reactions were carried out to assess fluoride incorporation for 
precursor (23). Amongst fluorination conditions tested the best incorporation yield was found 
at 100 °C for 100 min. in DMF using freshly prepared 1N TBAF/THF-solution (Scheme 5). 
The fluorinated intermediate (24) was purified by column chromatography on SiO2 and its 
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identity and purity (≥97%) confirmed by 1H/19F-NMR, HR-MS and analytical HPLC (see 
Supporting Information). Notably, the 19F-spectrum showed a set of 4 signals due to the 4 
diastereomers that the THP-protection yields. 
 
Scheme 5. Reagents and conditions: a) 1N TBAF/THF, DMF, 100 °C, 100 min, 19 %. 
 
The obtained intermediate 24 was used as a cold reference standard for co-elution on 
HPLC in order to identify the hot intermediate. 
 
Radiosynthesis of 18F-FAC 
 
       
18F-incorporation to form intermediate (25) was carried out using an Eckert & Ziegler 
modular system and appropriate software for radiosynthesis. The reaction parameters of 
solvent, temperature and reaction time were varied in order to determine optimal 18F-
incorporation conditions, using KHCO3 as base (Scheme 6). [18F]Fluoride was eluted from 
the QMA-cartridge using a K222/KHCO3-solution. Table 2 shows the calculated incorporation 
data, and Figure 5 shows 18F-incorporation plotted against the reaction temperature run in dry 
DMF as solvent. The highest incorporation values were obtained using DMF at 110 °C for 20 
minutes. Although MeCN or tBuOH as solvent failed to show any conversion, use of an 
alternative base such as TBA-OH or TBA-CO3 in MeCN or tBuOH might provide an 
alternative strategy. However, higher temperatures and longer reaction times led to decreased 
18F-incorporation in the arabino position due to the formation of the anhydro intermediate 
(Scheme 2). 18F-incorporation was calculated by peak integration of the crude reaction 
mixture after radiofluorination using radio-TLC (see Supporting Information). 
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Scheme 6. Radiofluorination was performed using different reaction conditions as outlined in the table below. 
 
Table 2. [18F]-incorporation results obtained under different conditions. 
 
 
Figure 5. [18F]-incorporation plotted against the reaction temperature run in dry DMF as solvent. 
 
The 18F-fluorinated intermediate (25) was confirmed by radio-HPLC (Figure 6) and 
co-injection of the 19F-containing reference standard (24) (see Supporting Information) after 
trapping the majority of the unreacted 18F-fluoride on a Sep-Pak alumina cartridge. The 
intermediate was eluted with 2.5 mL EtOAc into a new reaction vial. 
 
Figure 6. Radio-HPLC was performed in order to confirm the formation of 25. The fluoridation product was co-
eluted with reference compound 24 after 17.2 min (MeCN/H2O 10:1, flow rate 1 mL min-1). The profile of the 
radio-HPLC diagram is consistent with the radio-TLC diagram shown above. 
The solvent was then removed at 90 °C under a stream of nitrogen. 2N HCl solution was 
added to the dried residue (25) which was then stirred at 95 °C for 20 min (Scheme 7). A 
shorter deprotection time was found to lead to decreased final yields of the product 18F-FAC. 
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Scheme 7. Subsequent deprotection of the hot intermediate 25 using (a) 2N HCl at 95 °C for 20 min. A shorter 
deprotection time results in decreased final yields of the product 18F-FAC (1). 
After neutralization with 2N NaOH solution the mixture was loaded onto a semi-
preparative HPLC column via a 10 mL injection loop. [18F]-FAC was eluted after 22.5 
minutes at a flow rate of 3.5 mL/min using 3% MeCN in H2O as the mobile phase. Following 
concentration on the module (100 °C under a stream of nitrogen for 10 min.), the sample was 
taken up in sterile saline and an aliquot was co-eluted on an analytical HPLC in combination 
with both possible 2’-19F-isomers FC (26) and FAC (27) as references (Figures 7 and 8). 18F-
FAC was confirmed and its purity calculated to ≥98% with specific activity of ≥63 
GBq/µmol. The total synthesis time was 168 minutes, including the concentration and saline 
formulation time. Finally, 0.75-0.86 GBq of 18F-FAC were obtained resulting in 
radiochemical yields (RCY) of 4.3-5.5% (n = 8, decay-corrected from end of bombardment 
(EoB)). 
 
 
 
Figure 7. Radio-HPLC chromatogram of the purified fraction. Co-elution with both cold 2’-[19F]-isomers 26 
and 27 confirms that the correct stereoisomer was obtained. 
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Figure 8. Chemical structures of the two different “cold” 2’-fluoro-cytidines FC (26) and FAC (27). 
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Figure 9. Radio-HPLC traces recorded after radiofluorinations performed at different reaction temperatures. 
Additionally, a temperature study was performed to reveal why the 18F-incorporation 
decreases when the reaction temperature is increased. According to the mechanism 
intramolecular anhydro formation is expected at higher temperatures leading to a lower yield 
of the correct stereoisomer. Figure 9 shows radio-HPLC traces that were recorded after 
radiofluorination at 110 °C, 120 °C and 130 °C (20 min and 40 min) and co-elution with both 
2´-fluoro stereosisomers FC and FAC (bottom panel). The results show that higher 
temperatures do lead to anhydro formation and radiofluorination of the anhydro intermediate 
results in 18F-FC. The 18F-FAC/FC ratio decreases as the reaction temperature and time 
increase. 
Conclusions 
A novel radiochemical approach to 18F-FAC is described. For the first time, 18F-FAC 
was synthesized via late-stage radiofluorination of the intact pyrimidine nucleoside. Prior to 
synthesis, a novel fluorination precursor was designed using in silico methods and stability 
studies monitored by NMR. Precursor 23 was found to be a promising candidate for further 
testing out of the family of nucleosides that were investigated. 18F-incorporation studies led to 
optimal reaction conditions (110 °C, 20 minutes) that furnished 18F-FAC in 4.3-5.5% decay-
corrected radiochemical yield. Considering that this new process involves late-stage 
fluorination and labelling of a cytidine derivative (more challenging than the equivalent 
uridine derivative), our radiochemical yield is good. Our overall synthesis time (168 minutes) 
is similar to that reported one for 18F-FAC.[11] Even though early 18F-introduction gives a 
higher radiochemical yield, its automation is more difficult and the reliability and 
reproducibility is less easy to maintain. In addition, the radiochemical yield and overall 
radiosynthesis time of our methods might be further improvable using other synthesizers; 
alternatively one could obtain the same amount of labelled nucleoside product by starting 
with a higher 18F-activity. The reaction time for the radiolabelling step (20 minutes) is 
comparable with that used in the related 18F-FMAU radiosynthesis,[12] reflective of the 
similar steric hindrance around the 2’-position in these nucleoside precursors. Shorter 
reaction times for this radiolabelling step were found to lead to lower yields of product 
through incomplete reaction. 
Furthermore, it was shown that long reaction times and high reaction temperatures led 
to intramolecular anhydro-formation identified by the detection of 18F-FC. This study shows 
that rational precursor design can at least minimize the issue of side-product formation and 
hence can offer synthetic access of important PET radiotracer as a single stereoisomer. This 
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method should be transferable to GMP environments as it offers a quick and reproducible 2-
step-route towards 18F-FAC comparable to the radiosynthesis of 18F-FDG. However, further 
optimization is required in order to improve the radiochemical yield and prepare for transfer 
to production of clinical grade radiotracer. 
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Table 1. Calculated electron density Ω of selected cytidine (4-8) and 
uridine derivatives (9-11). 
#        R1 R2 R3 [Ω ± %]a 
4 
5 
6 
7 
8 
9 
10 
11 
H 
H 
H 
Boc 
phthalimide 
H 
Ac 
Boc 
Boc 
phthalimide 
 
 
 
 
 
H 
Boc 
NO2 
-0.911±0.09 
-0.901±0.05 
-0.860±0.01 
-0.825±0.06 
-0.814±0.08 
-0.838±0.02 
-0.770±0.03 
-0.589±0.10 
[a] Quantum chemically calculated net charge at the 2-carbonyl 
oxygen. 
 
Table 2. [18F]-incorporation results obtained under different 
conditions. 
 18 
# solvent T [°C] t [min] [18F]a [%] 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
MeCN 
tBuOH 
DMF 
DMF 
DMF 
DMF 
DMF 
DMF 
DMF 
DMF 
DMF 
DMF 
90 
95 
90 
95 
100 
105 
110 
110 
115 
120 
125 
130 
20 
20 
20 
20 
20 
20 
20 
30 
20 
20 
20 
20 
n/a 
n/a 
1.3±0.3 
2.6±0.2 
4.9±0.6 
7.7±0.8 
9.4±0.8 
7.9±0.6 
6.9±0.5 
4.1±0.4 
2.3±0.2 
1.8±0.2 
[a] [18F]-incorporation was calculated using radio-TLC. Each 
reaction was repeated three times under identical conditions. 
 
 
